Bronchogen

Lyochem primary owner

Overview

A member of the Khavinson class of short-peptide bioregulators, Bronchogen is the tetrapeptide Ala-Glu-Asp-Leu (AEDL) directed at respiratory-tissue regulatory pathways. The working hypothesis behind the whole family holds that short, tissue-specific peptide fragments act as endogenous regulators of cell-cycle and gene-expression programs in their target tissue; for Bronchogen, the Russian-school literature positions that target as bronchial epithelium and respiratory-tissue maintenance. Its origin traces to the St. Petersburg Institute of Bioregulation and Gerontology, where it was created as the series' respiratory entry. Its tissue-directed siblings include Cortagen (cerebral cortex, AEDP), Pinealon (cognitive, EDR), Vesugen (vascular, KED), and Cardiogen (cardiovascular). Lyochem supplies Bronchogen as a lyophilized reference standard in a 20 mg vial at ≥99.0% HPLC purity. CAS registration is inconsistent across suppliers for this bioregulator class, so identity rests on analytical data rather than a catalog number: the applicable batch COA can record LC-MS/MS sequence verification together with ESI-MS confirmation of the AEDL tetrapeptide mass. That explicit sequencing matters here because the family's tetrapeptides (AEDG / AEDL / AEDP / KED) fall close together in mass and cannot be told apart by intact mass alone. Chromatographic purity and residual-water content complete the release specification.

Applications & buyer fit

Specifications

CAS

Not consistently registered; see batch COA

Sequence

AEDL

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

20 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 30 minutes

MOQ

On request

Lead time

14–21 days

Storage

-20°C lyophilized; 2–8°C reconstituted, protect from light

Documentation available on request

• Lot-specific Certificate of Analysis (CoA)
• RP-HPLC chromatogram with peak integration
• ESI-MS identity confirmation (±0.5 Da)
• Sequence verification by LC-MS/MS
• Water content by Karl Fischer
• SDS / MSDS
• Source-literature pointer (Russian-language references on request)
• Stability at −20 °C across 12 months
• Sequence ladder available on request

Regulatory note

A Khavinson bioregulator of Russian scientific lineage, typically without a registered CAS. Per-batch COA data should confirm both the AEDL sequence and identity; because masses within the family sit close together, telling it apart from sibling tetrapeptides (AEDG / AEDP / KED) is essential.

Selected literature

1. Khavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781-791.
2. Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, Surkova EA, Platonova IS, Titova ON. Modulating effect of peptide therapy on the morphofunctional state of bronchial epithelium in rats with obstructive lung pathology. Bull Exp Biol Med. 2015;159(5):685-688.
3. Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Mosc). 2015;80(3):310-322.
4. Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, Khachidze DG, Lomidze EM, Jokhadze TA, Lezhava TA. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bull Exp Biol Med. 2011;150(3):375-377.
5. Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053.

Frequently asked questions